ReviewCancers2024

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse.

Maria Effrosyni Livanou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.